# Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

> **NCT04605094** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 194 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo / Benralizumab

## Key facts

- **NCT ID:** NCT04605094
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-12
- **Primary completion:** 2022-04-25
- **Final completion:** 2022-09-13
- **Target enrollment:** 194 (ACTUAL)
- **Why stopped:** The study did not meet the primary endpoint.
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605094, "Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04605094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*